From Milk to Medicine
In the past 30 years Pharming Group N.V. has successfully developed, produced and globally commercialised its own product. RUCONEST®, is a protein replacement therapy for the acute treatment of Hereditary Angioedema (HAE). The proprietary recombinant technology platform Pharming developed uses the milk of transgenic rabbits to produce high quality and large quantities of C1 esterase inhibitor, the protein missing in HAE patients. Due to its success in HAE, Pharming is also investigating the efficaciousness of RUCONEST® in other indications, such as pre-eclampsia and acute kidney injury. In addition, in order to commercialise RUCONEST® Pharming established an efficient marketing network in both the EU and the US, due to its success, the company also won a new ultra-rare disease product from Novartis, Leniolisib. This presentation will outline Pharming’s production process, its business strategy, expansion possibilities and what the future holds for Pharming.